%0 Journal Article
%T In utero delivery of targeted ionizable lipid nanoparticles facilitates in vivo gene editing of hematopoietic stem cells.
%A Palanki R
%A Riley JS
%A Bose SK
%A Luks V
%A Dave A
%A Kus N
%A White BM
%A Ricciardi AS
%A Swingle KL
%A Xue L
%A Sung D
%A Thatte AS
%A Safford HC
%A Chaluvadi VS
%A Carpenter M
%A Han EL
%A Maganti R
%A Hamilton AG
%A Mrksich K
%A Billingsley MB
%A Zoltick PW
%A Alameh MG
%A Weissman D
%A Mitchell MJ
%A Peranteau WH
%J Proc Natl Acad Sci U S A
%V 121
%N 32
%D 2024 Aug 6
%M 39078677
%F 12.779
%R 10.1073/pnas.2400783121
%X Monogenic blood diseases are among the most common genetic disorders worldwide. These diseases result in significant pediatric and adult morbidity, and some can result in death prior to birth. Novel ex vivo hematopoietic stem cell (HSC) gene editing therapies hold tremendous promise to alter the therapeutic landscape but are not without potential limitations. In vivo gene editing therapies offer a potentially safer and more accessible treatment for these diseases but are hindered by a lack of delivery vectors targeting HSCs, which reside in the difficult-to-access bone marrow niche. Here, we propose that this biological barrier can be overcome by taking advantage of HSC residence in the easily accessible liver during fetal development. To facilitate the delivery of gene editing cargo to fetal HSCs, we developed an ionizable lipid nanoparticle (LNP) platform targeting the CD45 receptor on the surface of HSCs. After validating that targeted LNPs improved messenger ribonucleic acid (mRNA) delivery to hematopoietic lineage cells via a CD45-specific mechanism in vitro, we demonstrated that this platform mediated safe, potent, and long-term gene modulation of HSCs in vivo in multiple mouse models. We further optimized this LNP platform in vitro to encapsulate and deliver CRISPR-based nucleic acid cargos. Finally, we showed that optimized and targeted LNPs enhanced gene editing at a proof-of-concept locus in fetal HSCs after a single in utero intravenous injection. By targeting HSCs in vivo during fetal development, our Systematically optimized Targeted Editing Machinery (STEM) LNPs may provide a translatable strategy to treat monogenic blood diseases before birth.